海利生物(603718.SH)：擬將楊凌金海76.07%股權轉讓給上海豪園
格隆匯11月11日丨海利生物(603718.SH)公佈，公司於2024年11月11日召開第五屆董事會第九次會議審議通過了《關於出售控股子公司股權暨關聯交易的議案》，擬將持有的楊凌金海76.07%股權轉讓給上海豪園。
鑑於楊凌金海截至2024年8月31日經審計的股東全部權益賬面價值為人民幣-20,164.44萬元，經評估的股東全部權益估值為人民幣-3,461.96萬元，故本次交易的股權轉讓價格為人民幣1元。作為本次交易實施的前置條件，上海豪園應代替楊凌金海償還完畢其對公司的債務（截至本公吿披露日，楊凌金海對公司的債務（含公司申請“上貸下用”的銀行貸款資金）本息合計人民幣244,577,211.47元）。本次交易完成後，公司將不再直接持有楊凌金海的股權，楊凌金海將不再納入公司合併報表範圍；且公司將收回所有對楊凌金海的借款並歸還有關銀行借款。
楊凌金海的唯一產品是口蹄疫疫苗。口蹄疫疫苗雖然是目前國內畜用生物製品體量最大的單品，但近幾年一方面受“非洲豬瘟”疫情等相關外部因素的影響導致整個“動保”發展面臨困境，行業景氣度下降；楊凌金海持續虧損，產品單一，後續業績提升難度較大，嚴重影響公司經營業績楊凌金海自成立以來，由於各種內外部的原因，始終處於虧損的狀態，近5年淨利潤就虧損2.5億元以上。
為應對“動保”業務日趨嚴峻的競爭形勢，公司一直在積極謀求向“人保”業務的轉型發展。隨着2024年公司通過實施重大資產重組完成對陝西瑞盛生物科技有限公司控制權的收購，公司的主營業務結構已完成了實質性升級轉變，“人保”業務的規模佔比將超過80%。從利潤來源角度看，更是100%的主營業務利潤均來源於“人保”業務，且不斷增長，而“動保”業務持續低迷，持續虧損。因此，剝離“動保”業務有利於公司實現真正向“人保”業務的轉型升級，有利於公司主營業務的清晰和聚焦。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
